Jump to main content
Jump to site search


Nuclear delivery of dual anti-cancer drugs by molecular self-assembly

Author affiliations

Abstract

Nanomedicines generally suffer from poor accumulation in tumor cells, low anti-tumor efficacy, and drug resistance. In order to address these problems, we introduced a novel nanomedicine based on dual anti-cancer drugs, which showed good cell nuclear accumulation properties. The novel nanomedicine consisted of three components: (1) dual anti-cancer drugs, 10-hydroxycamptothecin (HCPT) and chlorambucil (CRB), whose targets are located in the cell nucleus, (2) a nuclear localizing dodecapeptide, PMI peptide (TSFAEYWNLLSP), which could activate p53 by binding with MDM2 and MDMX located in the cell nucleus, and (3) an efficient self-assembling tripeptide FFY. Our nanomedicine exhibited enhanced cellular uptake and nuclear accumulation properties, thus achieving an excellent anti-cancer capacity both in vitro and in vivo. Our study will provide an inspiration for the development of novel multifunctional nanomaterials for cancer diagnosis and therapy.

Graphical abstract: Nuclear delivery of dual anti-cancer drugs by molecular self-assembly

Back to tab navigation

Supplementary files

Article information


Submitted
13 Jun 2020
Accepted
03 Aug 2020
First published
07 Sep 2020

Biomater. Sci., 2020, Advance Article
Article type
Paper

Nuclear delivery of dual anti-cancer drugs by molecular self-assembly

J. Wu, W. Ding, G. Han, W. You, W. Gao, H. Shen, J. Tang, Q. Tang and X. Wang, Biomater. Sci., 2020, Advance Article , DOI: 10.1039/D0BM00971G

Social activity

Search articles by author

Spotlight

Advertisements